$TCRT News

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

Alaunos Therapeutics Announces $1.12M Direct Offering Of 380,469 Shares And Warrants To Purchase Up To 386,654 Shares At $1.46 Per Share

Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors"

Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Alaunos’ ALN1003 Shows Statistically Significant Reduction In Liver Weight Independent Of Body Fat In Preclinical Analysis

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Therapeutics Reports Preclinical Results For ALN1003 Showing Weight Loss, Improved Insulin Sensitivity, And Better Liver Health In Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Alaunos Therapeutics Issues Updated Preclinical Data From Non-GLP Diet-Induced Obesity Mouse Studies Evaluating ALN1003, Investigational Oral Metabolic Therapeutic Candidate

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos Therapeutics Announces Early Data From Two Non-GLP DIO Mouse Studies Evaluating ALN1003 For Treating Obesity And Related Conditions

Ziopharm: Q3 Earnings Snapshot

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

Ziopharm: Q2 Earnings Snapshot

Alaunos Therapeutics Q2 EPS $(0.63) Up From $(0.71) YoY